# Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy

> **NCT04266028** · PHASE1 · COMPLETED · sponsor: **Desentum Oy** · enrollment: 27 (actual)

## Conditions studied

- Birch Pollen Allergy

## Interventions

- **BIOLOGICAL:** DM-101
- **BIOLOGICAL:** Placebo to match DM-101

## Key facts

- **NCT ID:** NCT04266028
- **Lead sponsor:** Desentum Oy
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-11
- **Primary completion:** 2021-05-31
- **Final completion:** 2021-05-31
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2023-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04266028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04266028, "Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04266028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*